Scadenza: 20 May 2021
Topic:
This topic aims at supporting activities that enable the conduct of vaccine & therapeutic trials to boost prevention and further inform public health policy and clinical management. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to two of the three expected outcomes listed below:
- Enrichment of the current portfolio of SARS-CoV-2 /COVID-19 prophylactics and therapeutics with clinical testing of promising candidates.
- Further development of new, or adjustment of existing, vaccine candidates to be effective against the current SARS-CoV-2 variants and potentially protect against new emerging ones.
- Development of new effective therapies against SARS-CoV-2 for the clinical management of COVID-19 disease, including for the prevention of disease progression to severe illness and hospitalisation.
Programma:
Horizon Europe Framework Programme (HORIZON)
Type of action:
HORIZON-RIA HORIZON Research and Innovation Actions
Ente finanziatore:
EU
Budget complessivo:
60.000.000 €
Who can participate:
Any legal entity, regardless of its place of establishment, including legal entities from nonassociated third countries or international organisations (including international European research organisations) is eligible to participate
Partnership: Mandatory
Status:
Closed
Quota finanziabile:
100%
Topic:
This topic aims at supporting activities that enable the conduct of vaccine & therapeutic trials to boost prevention and further inform public health policy and clinical management. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to two of the three expected outcomes listed below:
- Enrichment of the current portfolio of SARS-CoV-2 /COVID-19 prophylactics and therapeutics with clinical testing of promising candidates.
- Further development of new, or adjustment of existing, vaccine candidates to be effective against the current SARS-CoV-2 variants and potentially protect against new emerging ones.
- Development of new effective therapies against SARS-CoV-2 for the clinical management of COVID-19 disease, including for the prevention of disease progression to severe illness and hospitalisation.
Who can participate:
Any legal entity, regardless of its place of establishment, including legal entities from nonassociated third countries or international organisations (including international European research organisations) is eligible to participate
Programme:
Horizon Europe Framework Programme (HORIZON)
Type of action:
HORIZON-RIA HORIZON Research and Innovation Actions
Consortium: Required
Status: Open
Total budget:
60.000.000 €
Funding rate:
100%
Notes:
The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 10 million would allow these specific challenges to be addressed appropriately, with phase I trials expected to be at the lower end of this spectrum. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
